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BACKGROUND: Female survivors of pediatric Hodgkin lymphoma (HL) who have received chest radiotherapy are at increased risk of
breast cancer. Guidelines for early breast cancer screening among these survivors are based on little data regarding clinical outcomes.
This study reports outcomes of breast cancer screening with MRI and mammography (MMG) after childhood HL. METHODS: We eval-
uated the results of breast MRI and MMG screening among 96 female survivors of childhood HL treated with chest radiotherapy. Out-
comes measured included imaging sensitivity and specificity, breast cancer characteristics, and incidence of additional imaging and
breast biopsy. RESULTS: Median age at first screening was 30 years, and the median number of MRI screening rounds was 3. Ten
breast cancers were detected in 9 women at a median age of 39 years (range, 24-43 years). Half were invasive and half were preinva-
sive. The median size of invasive tumors was 8 mm (range, 3-15 mm), and none had lymph node involvement. Sensitivity and specific-
ity of the screening modalities were as follows: for MRI alone, 80% and 93.5%, respectively; MMG alone, 70% and 95%, respectively;
both modalities combined, 100% and 88.6%, respectively. All invasive tumors were detected by MRI. Additional investigations were
required in 52 patients, (54%), and 26 patients (27%) required breast biopsy, with 10 patients requiring more than 1 biopsy. CONCLU-
SIONS: Screening including breast MRI with MMG has high sensitivity and specificity in pediatric HL survivors, with breast cancers
detected at an early stage, although it is associated with a substantial rate of additional investigations. Cancer 2014;120:2507-13.
V C 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article
under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
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INTRODUCTION
Female survivors of pediatric Hodgkin’s lymphoma (HL) who have received chest radiotherapy (RT) are known to be
at increased risk of developing breast cancer.
1,2 Consequently, clinical practice guidelines have recommended the early
initiation of breast cancer screening among these survivors, with the expectation of reducing the risk of breast cancer–
related morbidity and mortality,
3-6 although there is evidence that compliance with recommended screening is poor.
7,8
A potentially significant limitation of the existing evidence is the scarcity of data regarding the outcome of screening
among survivors treated for HL during childhood. It cannot be assumed that outcomes of breast cancer screening among
patients treated and screened at older ages will apply to survivors of pediatric HL. The age at which RT is delivered and
the attained age of the patient at the time of screening affect both the absolute risk of breast cancerand the imaging charac-
teristics of the breast tissue.
9 Although the relative risk of breast cancer may be higher, the absolute risk (which has the
greater influence on the outcome of screening) may be lower among younger survivors. Further, the sensitivity of mam-
mography is worse among younger patients,
10,11 also potentially influencing the outcome of screening protocols among
survivors ofchildhoodHL.
Finally, existing data regarding the effectiveness of breast cancer screening preceded the routine use of MRI, which
has emerged as a preferred means of screening high-risk patients.
12,13 There are no published data regarding the outcomes
of childhoodcancer survivorsscreened withMRI.
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Original ArticleTo address these issues, we conducted a study of the
results of combined MRI and mammographic screening
among female pediatric HL patients treated with chest
RT, focusing on the characteristics of the detected breast
cancers and the need for additional investigations associ-
ated withbreastMRIscreening.
PATIENTS AND METHODS
Patientswereidentifiedfrompediatriclong-termaftercare
clinics at the Princess Margaret Cancer Centre and the
Dana-Farber Cancer Institute (DFCI). Patients were
identified from pediatric aftercare clinics, HL databases,
and survivorships organizations. Patients were included if
they had a prior diagnosis of HL before age 20 years, if
treatment had included chest RT, and if breast cancer
screening had commenced with at least 1 breast MRI.
Patients at the Princess Margaret Cancer Centre were
screened in a clinical setting if they were >8 years beyond
HL therapy or at least age 25, whichever was later, and
were recommended to have annual breast MRI, MMG,
and clinical examination. Patients from the DFCI were
screened as part of a prospective study that included
women who were 8 years beyond HL therapy and were
screened withannual MRIand MMGfor3 years.
Mammography examinations were performed using
full-field digital mammography machines (Senographe
2000D or Senographe Essentials, GE Healthcare, Mil-
waukee, WI; or Selenia Dimensions, Hologic, Bedford,
MA). All study participants underwent a 2-view mammo-
graphic study of each breast consisting of a craniocaudal
and mediolateral oblique view. Additional projections
and spotmagnificationviewswereused as needed.
Contrast-enhanced MRI examinations were per-
formed at 1.5-T scanner (Signa GE Healthcare, Milwau-
kee, WI; or Siemens Avanto, Siemens Medical Solutions,
Erlangen, Germany) or a 3-T scanner (Siemens Verio)
with use of a dedicated surface breast coil. Breast MRI
protocol evolved over the course of this study; however, in
all cases, it included bilateral fat-suppressed T2-weighted
images and both pre- and postcontrast T1-weighted
dynamicfatsuppressedimages.Spatialandtemporalreso-
lutionwerecompliantwithqualitystandardsoftheAmer-
ican CollegeofRadiology.
14
Dedicated breast radiologists reviewed MRI and
mammographic images. The study was approved by the
research ethics boards at the Princess Margaret Cancer
Centreand theDanaFaberCancer Institute.
Data Collection
Patient charts were reviewed and information regarding
patientdemographics,HL diagnosisand treatment,breast
cancer screening, additional investigations performed,
breastcancer diagnosis, and treatment were collected. Last
follow-up was taken as last clinical review or breast screen
imaging,whicheveroccurredlater.
Statistical Analysis
Descriptive statistics were used to describe the clinical fea-
tures of the cohort, the screening practices, and the addi-
tional testing caused by screen-detected findings, as well
as thebreastcanceroutcomes.
True-positive scans were those in which a breast
lesion was histologically proven to be an invasive breast
cancer or ductal carcinoma in situ (DCIS), and true-
negative scans were those that did not show a suspicious
breast lesion and no breast cancer was diagnosed in the
next 12months. False-negative scans were those scans that
did not detect a suspicious breast lesion, but a breast can-
cer was detected in the following 12 months, and false-
positive scans were those that resulted in a biopsy that was
subsequently benign. Additional tests included those tests
that were ordered outside the routine annual MMG and
MRI and included those ordered immediately and for
early screening. The cumulative breast cancer incidence in
the study cohort was calculated. Because there was no
competing causes of death in the study cohort, the esti-
mated cumulative breast cancer incidence was simply
equal to the complement of the Kaplan-Meier estimate of
survivalprobabilities.
RESULTS
Patient Characteristics
In total, 96 of 104 eligible patients (92.3%) were screened
with breast MRI from 2005 through 2012. Patient char-
acteristics with regard to initial HL treatment and risk fac-
tors for breast cancer are described in Table 1. Initial HL
diagnosis occurred between 1972 through 2003, and the
medianageatdiagnosiswas15years(2-19years).Theini-
tial treatment for HL was radiotherapy alone in 31
patients(32.3%)andcombinedradiationandchemother-
apy in 65 patients (67.7%). All patients received mediasti-
nal radiotherapy, with a median dose of 22.5 Gy (range,
14-45 Gy). The median dose for the DFCI patients was
36 Gy (14-45 Gy), and median dose for the Princess Mar-
garet patients was 15 Gy (15-35 Gy). Ninety percent of
patients received mantle radiation fields, with 10% receiv-
ing mediastinal-involved field radiotherapy excluding the
axillae. The most common chemotherapy agents used
were mechlorethamine, vincristine, procarbazine,
prednisone-doxorubicin (MOPP/ABVD) in 29 patients
(30.21%) and ABVD in 12 patients (12.5%). Seventy-
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of screening, and 74% had previous exposure to oral con-
traceptivepills orhormonereplacement.
Breast Cancer Screening
At the time that breast MRI screening commenced, 58
patients had had prior breast screening with MMG and/or
breast ultrasound (US). The median time from diagnosis
of HL to first breast MRI screen was 16 years (range, 5-39
years), and the median age at first MRI screen was 30 years
(range, 19-59 years). In total, 274 screening MRIs were
performed in 96 patients. The median number of MRI
screens was 3 (range, 1-7), and the median number of
MMG screens was 3 (range, 0-5). Eleven patients did not
receive MMG. Reasons included patient refusal (n510)
and breast-feeding (n51). Eight patients with at least 1
MRI dropped out of screening altogether (reasons not
stated), with an overall compliance rate 88 of 104
(84.6%).
Breast Cancer Detection
In the cohort of 96 women, 10 breast cancers were diag-
nosed in 9 women during 363 person-years of follow-up.
The 5-year cumulative incidenceof breast cancer from the
initiation of screening was 10.8% (95% CI, 3-17.4;
Fig. 1). The median screening round at which breast can-
cer was detected was screening round 2, although 4
patients were diagnosed with breast cancer at the time of
the first MRI screen. The median age of breast cancer di-
agnosis was 39 years (range, 24-43 years), and the median
latency period between HL diagnosis and age at breast
cancer diagnosis was 21 years (12-27 years). The locations
of the breast tumors were as follows: 6 were found in the
upper outer quadrant, 2 in the upper inner quadrant,
and 2 had an undocumented primary location. Eight
patients with a breast cancer detected had received mantle
radiotherapy fields, with 1 patient receiving radiation to
the mediastinum alone. RT dose was available for 89
patients. Among 61 patients who received >21 Gy to the
mediastinum, 8 (13%) were diagnosed with breast cancer,
in contrast to 1 of 28 patients (4%) who received <21 Gy
(4%); this difference was not statistically significant
(P5.17).
Characteristics of the diagnosed breast cancers are
summarized in Table 2. Half the tumors diagnosed were
invasive, and half were DCIS. The median size of invasive
tumor was 8 mm (range, 3-15 mm). All invasive tumors
were grade II or III. None of the detected breast cancers
was lymph node positive. At last time of follow-up, all
patientswerealive.
Of the 10 detected tumors, 5 were visible on both
MRI and MMG, 3 were visible only on MRI, and 2 were
detected on mammogram alone (both of which were
DCIS). The sensitivity of breast MRI was 80.0%, and
specificity was 93.5%, and the sensitivity and specificity
of MMG were 70.0% and 95.0% respectively. For breast
MRI and MMG combined, the sensitivity and specificity
were100%and 88.6%,respectively.
TABLE 1. Clinical Characteristics of 96 Female Sur-
vivors of Pediatric HL Screened With MRI/MMG
Age at HL diagnosis (y), median (range) 15 (2-19)
HL treatment, n (%)
Radiation alone 31 (32.3)
Chemotherapy1radiation 65 (67.7)
Radiation type
Mantle, n (%) 86 (90)
Mediastinal, n (%) 10 (10)
Radiation dose (Gy), median (range) 25.5 (14-45)
Chemo therapy, n (%)
None 31 (32%)
Alkylating 48 (50%)
Nonalkylating 14 (15%)
Unknown 3 (3%)
Menopausal status, n (%)
Premenopausal 75 (78)
Postmenopausal 18 (19)
Unknown 3 (3)
Hormone replacement therapy/
oral contraceptive pill use, n (%) 71 (74)
Yes 17 (18)
No 8 (8)
Unknown
Family history—first-degree relative, n (%) 4 (4)
Figure 1. Cumulative incidence of breast cancer starting at
time of first MRI screening.
MRI Breast Screening After Pediatric HL/Tieu et al
Cancer August 15, 2014 2509Additional Investigations
Of the 96 patients who were screened, 52 patients (54%)
required additional testing outside the planned annual
screen. These tests included those ordered immediately
following the index screening test as well as early rescreen-
ing recommended within 12 months because of findings
on the index screening test. Included in the additional
tests were 30 MRIs (3 immediate and 27 early),
26 MMGs (18 immediate and 8 early screening), and
65 breast ultrasounds (47 immediate and 18 early
screening).
Of all the additional tests, 123 (80%) were
prompted by an abnormality on an MRI that required
further investigation. The number of patients called back
for additional tests was highest at initial-screening MRI
and decreasedwithsubsequentbreastMRI(Table3).
Breast biopsy was performed in 26 patients (27%),
with 10 patients (10%) requiring more than 1 biopsy. Of
the 38 biopsies performed, 28 (74%) had benign pathol-
ogy, and of the 26 patients who underwent biopsy, 9 had
an invasive cancer or DCIS. The number of patients
undergoing benign biopsy was highest in the first screen-
ing round and decreased in subsequent rounds (Table 3).
Similarly, the number of benign biopsies was also highest
in the first screening round: among 28 benign biopsies
performedacrossallscreeningrounds,20(71%)wereper-
formed in the first screen, and 4, 3, and 1 were performed
in rounds 2, 3, and 4, respectively. Of the 28 benign
biopsies performed, 17 were prompted by an abnormality
on MRI, 6 were a result of an abnormality on MMG, and
5 were a result of an abnormality on both MRI and
MMG.
DISCUSSION
To our knowledge, this is the largest study to evaluate the
outcome of breast cancer screening among a cohort of at-
risk survivors of pediatric HL and the only study in which
MRI was employed for screening among all patients stud-
ied. When compared with prior reports with non-MRI
breast screening,
15,16 the breast cancers detected were
smaller, more likely to be preinvasive, and less likely to be
lymph node positive.Of the breast cancersdetected in our
study, 50% were preinvasive, with a median invasive size
of 8 mm (3-15 mm), and with none associated with
lymph node involvement. Terenziani et al reported on 86
pediatricpatientstreated withchest radiotherapy inwhich
screening imaging was predominantly with MMG and
breastultrasound.BreastMRIscreeningwasalsoincluded
but only occurred late in the overall screening series.
Tumors in that study were larger (median, 10 mm [range,
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2510 Cancer August 15, 20142-30 mm]), were more frequently node positive (6 of 11
patients), and were less likely to be noninvasive (2 of 11
patients) than the MRI-detected cases reported in our
cohort. Howell et al reported the outcome of the UK
National breast screening program for HL survivors, in
which survivors treated primarily as young adults under-
went mammography, with MRI used for young females
with mammographically dense breast tissue.
17 Interest-
ingly, among 417 patients invited to attend the program,
243 (58%) attended, with 5 breast cancers detected in the
program, none with axillary nodal involvement. In con-
trast, 7 of 13 breast cancers detected among nonattendees
involvedaxillarylymphnodes.Ourfindingssupportthese
results, illustrating the potential benefit of screening, but
also the challenge of attracting and retaining high-risk
patients inscreeningprograms.
MRI has emerged as the preferred modality for
screening women at high risk for breast cancer in other
clinical circumstances (eg, BRCA carriers). This is in part
attributable to evidence that MMG is less sensitive in
women younger than 40 years compared with those 40-49
years old,
11 primarily because increased mammographic
breast density is known to be inversely related to age. A
recent prospective study by Ng et al examined the addi-
t i o n a lb e n e f i to fb r e a s tM R It oM M Gi ns c r e e n i n gf o r
patients treated for HL <35 years, with the majority of
patients treated as adults.
18 This study found that MRI
was not more sensitive than MMG, with sensitivity of
68% for MMG and 67% for MRI. Other studies also
reporting MRI screening outcomes in older patients have
reported that the addition of MRI to mammography
increased the detection rate of early invasive cancers.
19,20 In
our group of pediatric survivors we found that when both
invasive and preinvasive tumors were considered, MRI had
a sensitivity of 80%, with both cases of false-negative MRIs
occurring with preinvasive disease. All cases of invasive
breast cancer in our study were detected by breast MRI at
an early stage. The finding of a higher sensitivity of MRI in
our study could be explained, in part, by the median age of
our cohort. Patients had a median age of 30 years when
MRI screening was commenced compared with a median
age of 37-43 years in prior studies.
19,20
The potential carcinogenicity of mammographic
radiation exposure has been the subject of concern.
21
Based on a quantitative synthesis of epidemiologic and
radiobiologic data, Heyes et al estimated that the benefits
of mammographic screening outweighed the potential
carcinogenicity risks for older average-risk women, but
that the potential risks among patients under age 50 sug-
gested a “need for caution.”
21 Our view is that the existing
risk of breast cancer among these survivors likely eclipses
the additional risk caused by mammography. However,
given that invasive cancers are reliably detected by MRI
alone, some patients may be willing to forgo the added
potential to detect DCIS with mammography in order to
avoid the additional radiation exposure and discomfort of
mammography, and the selection of imaging modality
shouldbe madeafterdiscussing theseissues.
The optimal time to initiate breast cancer screening
in childhood HL survivors is uncertain, and clinical prac-
tice guidelines vary in their recommendations on this
issue. Recommended start times typically include some
combination of 8- to 10-year latency from RT and an
attained age of 25-30 years.
4-6 In our view, the results of
this study support earlier start times within this range.
Four patients were found to have an existing breast cancer
at the time of their first screen, and 3 of these patients
were aged 30-35 years at the time of breast cancer detec-
tion. The youngest age at which breast cancer was
detected was 24 years old. This suggests that initiating
screening after age 30 may produce some delay in diagno-
sis, although we recognize that even the prevalent cancers
were detected at an early stage, and our sample size does
not permit accurate estimates of the number of patients
younger than 30 who would require screening to prevent
1 breast cancer death. Again, the initiation of screening at
age 25 potentially leads to >50 years of imaging, and for
thereasonsindicatedabove,somepatientsmayreasonably
opt to undergo MRI screening only if they have dense
breasttissue.
Current evidence suggests that pediatric patients
treated with chest radiotherapy have different breast can-
cer risks than HL patients treated at older ages. For exam-
ple, population-based studies have shown higher relative
risk for breast cancer development in patients who receive
radiotherapy between ages 10 and 14 years, with dimin-
ishing relative risks with increasing age.
1 Different base-
line breast cancer risk and breast density may contribute
to the differences found in mammographic sensitivity and
TABLE 3. Number of Patients Requiring Additional
Tests Per Screening Round
Screening MRI round
(n5number at risk)
Number of patients (n)1 ( n 596) 2 (n581) 3 (n565) 4 (n520)
Screening MRI, n (%) 96 (100%) 81 (100%) 65 (100%) 20 (100%)
Screening MMG, n (%) 72 (75%) 61 (75%) 57 (88%) 9 (45%)
Any additional test, n (%) 34 (35%) 14 (17%) 11 (17%) 2 (10%)
Benign biopsy, n (%) 11 (11%) 4 (5%) 3 (5%) 1 (5%)
Positive biopsy, n (%) 4 (4%) 1 (1%) 3 (5%) 2 (10%
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greaterimportancewhencomparedwitholderpatients.
Our findings also indicate that an important short-
coming ofMRI-basedscreeningamong youngsurvivors is
the high rate of additional investigations including biop-
sies that are precipitated by abnormal or ambiguous
screening results. More than half the screened patients
required an additional investigation, and 27% underwent
at least 1 biopsy. Forty-three patients (45%) without
breast cancer required additional testing, and 17 patients
(20%) had benign biopsies. Our rate of additional investi-
gation is higher than that described in a study of similar
patients predominantly screened with breast examination,
MMG, and breast ultrasound.
22 In that study only 12
patients (14%) without breast cancer required additional
testing, and 4 of these patients (5.3%) had benign biop-
sies.
22 Consistent with our findings, the authors of this
study found that with the introduction of MRI to their
screening program, the number of additional investiga-
tions increased. These results are consistent with studies
that examined MRI screening in other high-risk settings,
where there was a 3- to 5-fold increase in risk of recall for
investigation when the ultimate resultwas a benign lesion.
Notably, the frequency of additional screening declined
substantially over the first few screening rounds. The rate
of additional testing and invasive testing was important to
consider in this particular cohort, as additional testing can
be anxiety provoking in patients with elevated risk of
breast cancer.
23 In our experience, it is worthwhile to dis-
cuss the risk of additional investigations with patients in
advance of initiating screening and to provide appropriate
reassurance to allay worry that can be caused by call back
for additional investigations and to inform patients that
the risk of additional tests declines over the first few
rounds of screening. Recent studies suggest that character-
ization of the metabolic features of MRI-detected breast
lesions with proton MR spectroscopy may improve the
specificity of MRI and potentially reduce the frequency of
imaging-induced biopsy.
24
This study has limitations that warrant considera-
tion. Although it is the largest study of MRI breast screen-
ing in the target population described to date, it is not
possibletomakedefinitiveconclusionsregardingthemer-
its of this approach with regard to important outcomes
such as the prevention of breast cancer deaths. Moreover,
subset analyses were underpowered to detect what could
be clinically important differences in the breast cancer
detectionratethatcouldhelptoidentifytheoptimalcrite-
ria for screening. For example, the crude rate of breast
cancer detection among patients prescribed >21 Gy was
3-fold higher than that among patients prescribed lower
doses (comparable to those used in contemporary proto-
cols), although this difference was not statistically signifi-
cant. Given the reduction in breast dose associated with
smaller contemporary RT fields for pediatric HL, the
findings described here could be enhanced with a more
detailed evaluation of the radiation dose-risk relation than
we were able to provide. A larger study with longer
follow-up would be required to determine the outcomes
of screening among pediatric HL survivors treated exclu-
sively with contemporary RT doses and fields. In addi-
tion, there was some variability in the timing of screening
tests and the use of MMGbecause of the varietyin patient
acceptance and schedules. This did not allow side-by-side
comparison of the MRI and MMG findings in all screen-
ing rounds for all patients or an evaluation of the merit of
concurrent versus alternating MRI and MMG. We
believe, however, that any implementation of a screening
program among survivors would have similar variation in
theuseand timing ofdifferentmodalities.
Despitethese limitations thisstudy has providedim-
portant clinical information to aid in the use of breast
MRI screening in the pediatric HL aftercare population.
Specifically, clinically significant breast cancers are
detected at young ages and aree more likely to be found at
earlier stages compared with screening programs that do
not include MRI, although at the cost of requiring more
additional investigations and biopsy. We would recom-
mend complying with screening guidelines that recom-
mend screening from age 25 years or 8 years following
chestRT.
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